{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:17:55Z","timestamp":1790662675787,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Wendy Wilkinson of Micron Research Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To report antimicrobial resistance data for Gram-positive and Gram-negative pathogens isolated from paediatric patients in three hospitals in Kuwait during 2012\u201319.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In vitro activity of antimicrobials against isolates from documented infections was determined using CLSI broth microdilution method and breakpoints at a central laboratory. Enterobacterales and Pseudomonas aeruginosa isolates were screened for \u03b2-lactamases using multiplex PCR assays. Phenotypic determination of resistance in Haemophilus influenzae and Gram-positive isolates was performed using standard methodologies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 515 Enterobacterales isolates, 29.3% were ESBL-positive; susceptibility was highest to amikacin, ceftazidime\/avibactam and meropenem (\u226597.4%), regardless of ESBL status. CTX-M-15 was identified in 87.1% of ESBL-positive Escherichia coli and 84.2% of ESBL-positive Klebsiella pneumoniae isolates. Of 111 P. aeruginosa isolates, 9.9% were MDR and 12.6% meropenem-resistant (MEM-R). Amikacin and ceftazidime\/avibactam had the highest susceptibility rates in the overall group (\u226592.8%), with reduced rates among MDR and MEM-R isolates. All 269 MRSA and 180 MSSA isolates were susceptible to daptomycin, linezolid, teicoplanin, tigecycline and vancomycin. All MSSA and 99.3% of MRSA were ceftaroline susceptible. All 168 pneumococcal isolates were susceptible to ceftaroline, linezolid, tigecycline and vancomycin. H. influenzae and Streptococcus pyogenes ceftaroline susceptibility rates were \u226593.3% and \u226595.6%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Most isolates of Enterobacterales (including resistant phenotypes) and P. aeruginosa from Kuwait during 2012\u201319 were susceptible to ceftazidime\/avibactam. Ceftaroline was active against most Gram-positive isolates, including resistant phenotypes, and ESBL-negative Enterobacterales. These results indicate that novel antibiotics such as ceftazidime\/avibactam and ceftaroline represent valuable treatment options for paediatric infections, including those caused by MDR organisms.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlab159","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T23:40:36Z","timestamp":1633650036000},"source":"Crossref","is-referenced-by-count":13,"title":["Evaluation of the <i>in vitro<\/i> activity of ceftaroline, ceftazidime\/avibactam and comparator antimicrobial agents against clinical isolates from paediatric patients in Kuwait: ATLAS data 2012\u201319"],"prefix":"10.1093","volume":"3","author":[{"given":"Noura","family":"Al-Sweih","sequence":"first","affiliation":[{"name":"Department of Microbiology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7301-0144","authenticated-orcid":false,"given":"Wafaa","family":"Jamal","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiman","family":"Mokaddas","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7109-767X","authenticated-orcid":false,"given":"Nervana","family":"Habashy","sequence":"additional","affiliation":[{"name":"Pfizer Gulf FZ LLC, Pfizer Building, PO Box 502749, Dubai Media City, Dubai, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1765-8856","authenticated-orcid":false,"given":"Ayman","family":"Kurdi","sequence":"additional","affiliation":[{"name":"Pfizer Gulf FZ LLC, Pfizer Building, PO Box 502749, Dubai Media City, Dubai, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0573-1721","authenticated-orcid":false,"given":"Naglaa","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Pfizer Inc, 235 E 42nd St, New York, NY 10017, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"key":"2021121102163619200_dlab159-B1","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/jac\/dkaa065","article-title":"Progress towards a coordinated, national paediatric antimicrobial resistance surveillance programme: Staphylococcus aureus, enterococcal and Gram-negative bacteraemia in Australia","volume":"75","author":"Campbell","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2021121102163619200_dlab159-B2","doi-asserted-by":"crossref","first-page":"i31","DOI":"10.1093\/jac\/dkt024","article-title":"Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals","volume":"68 Suppl 1","author":"Adam","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2021121102163619200_dlab159-B3","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/INF.0000000000000652","article-title":"Antibiotic resistance prevalence in routine bloodstream isolates from children\u2019s hospitals varies substantially from adult surveillance data in Europe","volume":"34","author":"Bielicki","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"2021121102163619200_dlab159-B4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s12519-018-0195-x","article-title":"World Society for Pediatric Infectious Diseases declaration on combating antimicrobial resistance in children","volume":"14","author":"Buttery","year":"2018","journal-title":"World J Pediatr"},{"key":"2021121102163619200_dlab159-B5","doi-asserted-by":"crossref","first-page":"106104","DOI":"10.1016\/j.ijantimicag.2020.106104","article-title":"Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: a consensus paper","volume":"56","author":"Al Salman","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2021121102163619200_dlab159-B6","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jiph.2021.04.009","article-title":"Promoting cross-regional collaboration in antimicrobial stewardship: Findings of an infectious diseases working group survey in Arab countries of the Middle East","volume":"14","author":"Al Salman","year":"2021","journal-title":"J Infect Public Health"},{"key":"2021121102163619200_dlab159-B7","doi-asserted-by":"crossref","first-page":"e379\u201394","DOI":"10.1016\/S1473-3099(18)30414-6","article-title":"Epidemiology of common resistant bacterial pathogens in the countries of the Arab League","volume":"18","author":"Moghnieh","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021121102163619200_dlab159-B8","author":"WHO","year":"2021"},{"key":"2021121102163619200_dlab159-B9","author":"JMI Laboratories. SENTRY Antimicrobial Surveillance Program","year":"2021"},{"key":"2021121102163619200_dlab159-B10","author":"Pfizer","year":"2021"},{"key":"2021121102163619200_dlab159-B11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1128\/CMR.18.2.417-422.2005","article-title":"Diagnosis and management of pediatric urinary tract infections","volume":"18","author":"Zorc","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"2021121102163619200_dlab159-B12","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMra011994","article-title":"Community acquired pneumonia in children","volume":"346","author":"McIntosh","year":"2002","journal-title":"N Engl J Med"},{"key":"2021121102163619200_dlab159-B13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.pcl.2013.12.004","article-title":"Cutaneous bacterial infections caused by Staphylococcus aureus and Streptococcus pyogenes in infants and children","volume":"61","author":"Larru","year":"2014","journal-title":"Pediatr Clin North Am"},{"key":"2021121102163619200_dlab159-B14","author":"Global Alliance for Infections in Surgery","year":"2021"},{"key":"2021121102163619200_dlab159-B15","volume-title":"Summary of Product Characteristics","author":"Zinforo (ceftaroline fosamil)","year":"2017"},{"key":"2021121102163619200_dlab159-B16","volume-title":"Summary of Product Characteristics","author":"Zavicefta","year":"2020"},{"key":"2021121102163619200_dlab159-B17","author":"CLSI","year":"2018"},{"key":"2021121102163619200_dlab159-B18","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1128\/AAC.05186-14","article-title":"Trends in susceptibility of Escherichia coli from intra-abdominal infections to and comparators in the United States according to data from the SMART program, 2009\u20132013","volume":"59","author":"Lob","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121102163619200_dlab159-B19","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1128\/AAC.00220-16","article-title":"In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014)","volume":"60","author":"Nichols","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121102163619200_dlab159-B20","volume-title":"Essential Procedures for Clinical Microbiology","author":"Isenberg","year":"1998"},{"key":"2021121102163619200_dlab159-B21","author":"CLSI","year":"2021"},{"key":"2021121102163619200_dlab159-B22","first-page":"e523\u20139","article-title":"Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing position statements on polymyxin b and colistin clinical breakpoints","volume":"71","author":"Satlin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021121102163619200_dlab159-B23","volume-title":"Summary of Product Characteristics","author":"Tygacil (tigecycline)","year":"2020"},{"key":"2021121102163619200_dlab159-B24","doi-asserted-by":"crossref","first-page":"e1001974","DOI":"10.1371\/journal.pmed.1001974","article-title":"Antibiotic resistance in India: drivers and opportunities for action","volume":"13","author":"Laxminarayan","year":"2016","journal-title":"PLoS Med"},{"key":"2021121102163619200_dlab159-B25","volume-title":"Scoping Report on Antimicrobial Resistance in India","author":"Gandra","year":"2017"},{"key":"2021121102163619200_dlab159-B26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4103\/ijmm.IJMM_17_415","article-title":"Antimicrobial susceptibility profiles of Gram-negative bacteria causing infections collected across India during 2014\u20132016: Study for monitoring antimicrobial resistance trend report","volume":"36","author":"Veeraraghavan","year":"2018","journal-title":"Indian J Med Microbiol"},{"key":"2021121102163619200_dlab159-B27","first-page":"143","article-title":"High levels of antimicrobial resistance at a tertiary trauma care centre of India","volume":"133","author":"Behera","year":"2011","journal-title":"Indian J Med Res"},{"key":"2021121102163619200_dlab159-B28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/ijmm.IJMM_16_427","article-title":"Prevalence and genetic mechanisms of antimicrobial resistance in Staphylococcus species: A multicentre report of the Indian Council of Medical Research Antimicrobial Resistance Surveillance Network","volume":"35","author":"Rajkumar","year":"2017","journal-title":"Indian J Med Microbiol"},{"key":"2021121102163619200_dlab159-B29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jgar.2016.07.008","article-title":"Prevalence and genotype distribution of methicillin-resistant Staphylococcus aureus (MRSA) in India","volume":"7","author":"Sunagar","year":"2016","journal-title":"J Glob Antimicrob Resist"},{"key":"2021121102163619200_dlab159-B30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/CMR.00096-12","article-title":"\u03b2-lactamase production in key Gram-negative pathogen isolates from the Arabian Peninsula","volume":"26","author":"Zowawi","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"2021121102163619200_dlab159-B31","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.3390\/microorganisms8101626","article-title":"Retrospective analysis on antimicrobial resistance trends and prevalence of \u03b2-lactamases in Escherichia coli and ESKAPE pathogens isolated from Arabian patients during 2000\u20132020","volume":"8","author":"Nasser","year":"2020","journal-title":"Microorganisms"},{"key":"2021121102163619200_dlab159-B32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/1120009X.2018.1438768","article-title":"Comparative in vitro activity of ceftaroline and comparator agents against nosocomial Gram-negative and Gram-positive clinically significant bacterial isolates from patients in a teaching hospital in Kuwait","volume":"30","author":"Jamal","year":"2018","journal-title":"J Chemother"},{"key":"2021121102163619200_dlab159-B33","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1128\/AAC.02286-15","article-title":"Activity of ceftazidime-avibactam against extended-spectrum- and AmpC \u03b2-lactamase-producing Enterobacteriaceae collected in the INFORM Global Surveillance Study from 2012 to 2014","volume":"60","author":"Karlowsky","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121102163619200_dlab159-B34","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1099\/jmm.0.019208-0","article-title":"Transmission of a Klebsiella pneumoniae clone harbouring genes for CTX-M-15-like and SHV-112 enzymes in a neonatal intensive care unit of a Kuwaiti hospital","volume":"59","author":"Dashti","year":"2010","journal-title":"J Med Microbiol"},{"key":"2021121102163619200_dlab159-B35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000321242","article-title":"Sequence analysis of blaCTX-M genes carried by clinically significant Escherichia coli isolates in Kuwait hospitals","volume":"20","author":"Al Hashem","year":"2011","journal-title":"Med Princ Pract"},{"key":"2021121102163619200_dlab159-B36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0732-8893(97)00180-6","article-title":"The prevalence and antibiotic susceptibility pattern of Gram-negative bacterial isolates in two ICUs in Saudi Arabia and Kuwait","volume":"30","author":"Rotimi","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021121102163619200_dlab159-B37","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jpedsurg.2010.12.001","article-title":"A 4-year prospective study of septicemia in pediatric surgical patients at a tertiary care teaching hospital in Kuwait","volume":"46","author":"Mokaddas","year":"2011","journal-title":"J Pediatr Surg"},{"key":"2021121102163619200_dlab159-B38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/jhin.1999.0608","article-title":"An analysis of hospital-acquired bacteraemia in intensive care unit patients in a university hospital in Kuwait","volume":"43","author":"Jamal","year":"1999","journal-title":"J Hosp Infect"},{"key":"2021121102163619200_dlab159-B39","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1128\/AAC.02050-13","article-title":"Molecular characterization of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in the countries of the Gulf Cooperation Council: dominance of OXA-48 and NDM producers","volume":"58","author":"Zowawi","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121102163619200_dlab159-B40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/mdr.2014.0123","article-title":"Emergence of new sequence type OXA-48 carbapenemase-producing Enterobacteriaceae in Kuwait","volume":"21","author":"Jamal","year":"2015","journal-title":"Microb Drug Resist"},{"key":"2021121102163619200_dlab159-B41","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1099\/jmm.0.059915-0","article-title":"High prevalence of VIM-4 and NDM-1 metallo-\u03b2-lactamase among carbapenem-resistant Enterobacteriaceae","volume":"62","author":"Jamal","year":"2013","journal-title":"J Med Microbiol"},{"key":"2021121102163619200_dlab159-B42","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1099\/jmm.0.000730","article-title":"Identification of carbapenem-resistant Pseudomonas aeruginosa in selected hospitals of the Gulf Cooperation Council States: dominance of high-risk clones in the region","volume":"67","author":"Zowawi","year":"2018","journal-title":"J Med Microbiol"},{"key":"2021121102163619200_dlab159-B43","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.diagmicrobio.2016.07.012","article-title":"In vitro activity of ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012\u20132014","volume":"86","author":"Karlowsky","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021121102163619200_dlab159-B44","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jgar.2020.12.013","article-title":"In vitro activity of ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in the Middle East and Africa: AWARE global surveillance programme 2015\u20132018","volume":"24","author":"Karlowsky","year":"2021","journal-title":"J Glob Antimicrob Resist"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/3\/4\/dlab159\/41537538\/dlab159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/3\/4\/dlab159\/41537538\/dlab159.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T03:46:08Z","timestamp":1639194368000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlab159\/6453865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlab159","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,9,30]]},"article-number":"dlab159"}}